Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
World J Gastroenterol. 2019 Dec 14;25(46):6767-6780. doi: 10.3748/wjg.v25.i46.6767.
Recent advances in endoscopic technology, especially magnifying endoscopy with narrow band imaging (ME-NBI) enable us to detect superficial esophageal squamous cell carcinoma (ESCC), but determining the appropriate method of resection, endoscopic resection (ER) surgical resection, is often challenging. Recently, several studies have reported that F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a useful indicator for decision-making regarding treatment for superficial ESCC. Although, there are not enough reports on association between FDG-PET uptake and clinicopathological characteristics of superficial ESCC. And, there are not enough reports on evaluating the usefulness of combination of FDG-PET and ME-NBI for determining the treatment strategy for superficial ESCC. This study evaluated clinical relevance of FDG-PET and ME-NBI in decision-making regarding the treatment strategy for ESCC.
To investigate the association between FDG uptake and the clinicopathological characteristics of superficial ESCC and its usefulness of combination of FDG-PET and ME-NBI for determining the treatment strategy for superficial ESCC.
A database of all patients with superficial ESCC who had undergone both ME-NBI and FDG-PET for pre-treatment staging at Aichi Cancer Center Hospital between January 2008 and November 2018 was retrospectively analyzed. FDG uptake was defined positive or negative whether the primary lesion was visualized or could be distinguished from the background, or not. The invasion depth of ESCC was classified according to the Japan Esophageal Society. Primary endpoint is to evaluate the association between FDG uptake and clinicopathological characteristics of superficial ESCC. Secondary endpoint is to investigate the efficacy of combination of FDG-PET and ME-NBI for determining the treatment strategy for superficial ESCC.
A total of 82 lesions in 82 patients were included. FDG-PET showed positive uptake in 29 (35.4%) lesions. Univariate analysis showed that uptake of FDG-PET had significant correlations with circumferential extension ( = 0.014), pathological depth of tumor invasion ( < 0.001), infiltrative growth pattern ( < 0.001), histological grade ( = 0.002), vascular invasion ( = 0.001), and lymphatic invasion ( < 0.001). On multivariate analysis, only depth of tumor invasion was independently correlated with FDG-PET/computed tomography visibility ( = 0.018). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of Type B2 in ME-NBI for the invasion depth of T1a muscularis mucosae and T1b upper submucosal layer were 68.4%/79.4%/50.0%/89.3%/76.8%, respectively, and those of Type B3 for the depth of T1b middle and deeper submucosal layers (SM2 and SM3) were 46.7%/100%/100%/89.3%/90.2%, respectively. On the other hand, those of FDG-PET for SM2 and SM3 were 93.3%/77.6%/48.2%/98.1%/80.5%, respectively, whereas, if the combination of positive FDG uptake and type B2 and B3 was defined as an indicator for radical esophagectomy or definitive chemoradiotherapy, the sensitivity, specificity, PPV, NPV, and accuracy were 78.3%/91.5%/78.3%/91.5%/87.8%, respectively.
FDG uptake was correlated with the invasion depth of superficial ESCC. Combined use of FDG-PET and ME-NBI, especially with the microvascular findings of Type B2 and B3, is useful to determine whether ER is indicated for the lesion.
内镜技术的最新进展,尤其是窄带成像放大内镜(ME-NBI),使我们能够检测到浅表性食管鳞状细胞癌(ESCC),但确定适当的切除方法(内镜切除术[ER]或手术切除术)通常具有挑战性。最近,有几项研究报告称,氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)是决策治疗浅表性 ESCC 的有用指标。尽管,关于 FDG-PET 摄取与浅表性 ESCC 的临床病理特征之间的关联的报告还不够多。并且,关于评估 FDG-PET 和 ME-NBI 联合用于确定浅表性 ESCC 治疗策略的有效性的报告也不够多。本研究评估了 FDG-PET 和 ME-NBI 在决策 ESCC 治疗策略中的临床相关性。
探讨 FDG 摄取与浅表性 ESCC 的临床病理特征之间的关联,以及 FDG-PET 和 ME-NBI 联合用于确定浅表性 ESCC 治疗策略的有效性。
回顾性分析了 2008 年 1 月至 2018 年 11 月期间在爱知癌症中心医院接受 ME-NBI 和 FDG-PET 治疗进行术前分期的所有浅表性 ESCC 患者的数据库。如果原发性病变可被观察到或可与背景区分开来,则将 FDG 摄取定义为阳性或阴性,否则为阴性。ESCC 的浸润深度根据日本食管学会进行分类。主要终点是评估 FDG 摄取与浅表性 ESCC 的临床病理特征之间的关联。次要终点是研究 FDG-PET 和 ME-NBI 联合用于确定浅表性 ESCC 治疗策略的疗效。
共纳入 82 例患者的 82 个病变。29 个(35.4%)病变的 FDG-PET 显示阳性摄取。单因素分析显示,FDG-PET 摄取与环周延伸( = 0.014)、肿瘤病理浸润深度( < 0.001)、浸润性生长模式( < 0.001)、组织学分级( = 0.002)、血管侵犯( = 0.001)和淋巴侵犯( < 0.001)显著相关。多因素分析显示,仅肿瘤浸润深度与 FDG-PET/计算机断层扫描可见性独立相关( = 0.018)。ME-NBI 对 T1a 黏膜肌层和 T1b 浅层黏膜下层的 T1a 黏膜肌层和 T1b 浅层黏膜下层的侵犯深度的 B2 型的灵敏度、特异性、阳性预测值(PPV)、阴性预测值(NPV)和准确率分别为 68.4%/79.4%/50.0%/89.3%/76.8%,而 B3 型对 T1b 中层和深层黏膜下层(SM2 和 SM3)的深度的灵敏度、特异性、PPV、NPV 和准确率分别为 46.7%/100%/100%/89.3%/90.2%。另一方面,SM2 和 SM3 的 FDG-PET 的灵敏度、特异性、PPV、NPV 和准确率分别为 93.3%/77.6%/48.2%/98.1%/80.5%,如果将阳性 FDG 摄取和 B2 型和 B3 型结合定义为根治性食管切除术或明确放化疗的指标,则灵敏度、特异性、PPV、NPV 和准确率分别为 78.3%/91.5%/78.3%/91.5%/87.8%。
FDG 摄取与浅表性 ESCC 的浸润深度相关。FDG-PET 和 ME-NBI 的联合使用,特别是结合 B2 型和 B3 型的微血管发现,有助于确定 ER 是否适用于该病变。